Anteris Technologies Global (NASDAQ:AVR) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Anteris Technologies Global (NASDAQ:AVR) issued its quarterly earnings data on Tuesday. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03, FiscalAI reports. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $2.75 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%.

Anteris Technologies Global Stock Down 0.8%

Shares of AVR traded down $0.05 during mid-day trading on Tuesday, hitting $5.89. The stock had a trading volume of 778,730 shares, compared to its average volume of 1,161,049. Anteris Technologies Global has a fifty-two week low of $3.30 and a fifty-two week high of $11.06. The company has a market cap of $574.04 million, a PE ratio of -3.02 and a beta of 2.02. The company’s fifty day simple moving average is $7.18 and its two-hundred day simple moving average is $7.39.

Insider Activity

In other news, major shareholder L1 Capital Pty Ltd acquired 272,695 shares of Anteris Technologies Global stock in a transaction that occurred on Tuesday, October 6th. The shares were purchased at an average cost of $7.18 per share, for a total transaction of $1,957,950.10. Following the completion of the purchase, the insider directly owned 6,358,271 shares of the company’s stock, valued at $45,652,385.78. This trade represents a 4.48% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders purchased 1,554,730 shares of company stock worth $11,694,513. Corporate insiders own 4.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AVR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Wednesday, August 26th. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price target on shares of Anteris Technologies Global in a report on Wednesday, October 14th. Finally, Barclays upgraded Anteris Technologies Global to a “hold” rating in a research note on Wednesday, October 7th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Anteris Technologies Global has a consensus rating of “Hold” and an average price target of $14.00.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.